Quanergy’s 3D LiDAR Solution Selected for First V2X Smart City Deployment in Korea
20.7.2021 13:00:00 EEST | Business Wire | Press release
Quanergy Systems, Inc., a leading provider of OPA-based solid state LiDAR sensors and smart 3D solutions for automotive and IoT, today announced its 3D LiDAR solution has been selected to support the development of an Information, Communication, and Technology (ICT) system in Busan, South Korea. The ICT system is a key component of the South Korean government’s strategy to build data driven IoT smart cities. Busan is one of the pilot cities for the initiative.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210720005414/en/
Quanergy's 3D LiDAR Solution Selected for First V2X Smart City Deployment in Korea (Photo: Business Wire)
Deployed in collaboration with long-time system integrator partner iCent, Quanergy’s 3D solution, consisting of its MQ-8 LiDAR sensor, paired with its proprietary perception software QORTEX DTC™, collects and analyzes traffic data, including the walking direction of pedestrians, their traffic volume, and the number of speeding vehicles, enabling the iSaver data analytics platform from iCent to determine their patterns based on time of day, day of the week, etc.
The collected data enables Busan’s smart city traffic center to better understand traffic patterns, predict safety hazards, and ultimately develop transportation policies to improve pedestrian safety. This information is crucial for ICT infrastructure to inform smarter, data-driven decisions. Furthermore, the solution integrates with traffic lights to respond dynamically to traffic, and gives drivers and pedestrians visibility into real-time traffic information through an app on their smartphones. This is the first system of its kind in Korea to provide traffic data for V2X (Vehicle to Everything) equipment and beacon equipment.
“Quanergy’s LiDAR solution provided greater than 95% accuracy and reliable performance in all ambient conditions, day or night,” said Moon, WonSang, CEO at iCENT, “With more accurate data, Busan was able to improve the effectiveness of its transportation policies. In addition, the LiDAR solution provided a low total cost of ownership, for a cost savings of more than 30%. The use of LiDAR also automated the data collection, eliminating the need for manual, error-prone data collection methods.”
In 2020, Quanergy installed its Smart LiDAR solution in Seoul, South Korea, to improve crosswalk safety in school zones.
To learn more about the Busan Smart City Project, see our case study.
About Quanergy Systems, Inc.
Quanergy Systems’ mission is to create powerful, affordable smart LiDAR solutions for automotive and IoT applications to enhance people’s experiences and safety. Quanergy has developed the only true 100% solid state CMOS LiDAR sensor built on optical phased array (OPA) technology to enable the mass production of low-cost, highly reliable 3D LiDAR solutions. Through Quanergy’s smart LiDAR solutions, businesses can now leverage real-time, advanced 3D insights to transform their operations in a variety of industries including industrial automation, physical security, smart cities, smart spaces, and much more. Quanergy solutions are deployed by over 350 customers across the globe. For more information, please visit us at www.quanergy.com.
About iCENT
Founded in February 2000, iCENT Co., Ltd. provides technology information and communication solutions, mostly for Total Network, Security and Safety Platform Solutions (i-Saver). iCENT is a one-stop service company that has developed network analysis and management products and now provides network consulting, design, construction and operation support. Through specialized solutions for mobile and video, the company provides professional technology centering on leading service providers and SO / MSOs in Korea. iCENT has also diversified its business portfolio through various new businesses related to network and computing and has expanded its business opportunities with network-based system integration to increase customer value. For more information, visit www.icent.co.kr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005414/en/
Contact information
Quanergy
Neal Stein
Media@quanergy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom